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Introduction {#s1}
============

End-stage renal disease (ESRD) is a clinical condition with uremic syndrome which has a very poor prognosis for patients ([@R1]). It is one of the most important life-threatening diseases in the world, incurring considerable social and economic burden on patients, their families and society ([@R2]). Patients with ESRD need medical intervention as well as supportive care including hemodialysis, peritoneal dialysis, or kidney transplantation. Since many of these patients are not eligible for kidney transplantation, they should be treated via dialysis ([@R3]). Hemodialysis is the most common treatment strategy for kidney failure, for which either an arteriovenous graft, central venous catheters (CVC), arterialvenous shunted external arteriovenous fistula is used for vascular access ([@R4]).

Although the use of CVC has played an important role in modern medicine, it is an important cause of morbidity and mortality in hospitals ([@R3]). Because of the use of central catheter, catheter-related bloodstream infection (CRBSI) is one of the most common fatal complications ([@R5]). It is estimated that 200,000 cases of CRBSI occur in the U.S. and its related mortality has been approximately estimated to be about 12-25% ([@R6]). In a study on 68 children, from 2000 to 2005, in the dialysis unit of a Children's Hospital in Mashhad (Iran), the central vein catheter-related infection was reported to be about 48% ([@R3]).CRBSI increases the length of stay around 4.2 to 5.7 days, and it has an increasing trend ([@R7]).

Prevention of bacterial infection is very important ([@R8]). In addition to good clinical practices to prevent catheter-related infection, the use of the subclavian vein as the best anatomic site, and utilization of impregnating catheters with antiseptics or antibiotics could also effectively prevent potential infection ([@R9]). The benefits of using gentamicin, cephalosporins, minocycline, and a high concentration of citrate in reducing catheter-related bacteremia(CRB) rate have been reported ([@R10]). However, because of the risks related to leakage of circulating antibiotics and development of resistance to antibiotics, it is replaced by taurolidine-citrate lock solution ([@R8]). It is appropriate for short- and long-term catheter and is made of 2% taurolidine, as an anti-microbial agent (with a broad spectrum of activity against gram-positive and gram-negative organisms and fungi) and 4% citrate to prevent thrombus formation. Taurolidine-citrate is not an antibiotic and no in vitro antimicrobial resistance has been reported yet ([@R11]). Recently, it has become available in Iran, but it is not covered by health insurances because of doubts about its efficacy and cost-effectiveness compared to the current alternative (heparin).

In this study, as a part of health technology assessment (HTA) project and according to our former HTA studies ([@R12]-[@R15]), both the efficacy and cost- effectiveness of taurolidine-citrate was evaluated as a hemodialysis catheter lock solution in Iran.

Research Questions {#s1-1}
------------------

1.  1\) What is the cost of taurolidine-citrate in Iran when used to prevent catheter-related infections in hemodialysis patients‏?

2.  2\) How much does heparin cost in Iran when used to prevent catheter-related infections in hemodialysis patients‏?

3.  3\) How much does heparin-gentamicin cost in Iran when used to prevent catheter-related infections in hemodialysis patients‏?

4.  4\) How much does the ICER of taurolidine-citrate cost in Iran compared to heparin in the prevention of catheter-related infections in hemodialysis patients‏?

5.  5\) How much does the ICER of taurolidine-citrate cost compared to heparin-gentamicin in the prevention of catheter-related infections in hemodialysis patients in Iran‏?

Study Objectives {#s1-2}
----------------

1.  1\) According to the systematic review, taurolidine-citrate is safer than heparin in the prevention of catheter-related infections in hemodialysis patients‏.

2.  2\) According to the systematic review, taurolidine-citrate is safer than heparin-gentamicin in the prevention of catheter-related infections in hemodialysis patients‏.

3.  3\) According to the systematic review, taurolidine-citrate is more cost effective than heparin in the prevention of catheter-related infections in hemodialysis patients‏.

4.  4\) According to the systematic review, taurolidine-citrate is more cost effective than heparin-gentamicin in preventing catheter-related infections in hemodialysis patients‏.

Methods {#s2}
=======

1) Systematic Review {#s2-1}
--------------------

*Data Sources:* To evaluate the efficacy of taurolidine solution lock, a systematic review was conducted through searching studies published from 1996 to the end of 2013 in electronic databases including PubMed, ISI Web of Science, Scopus, and Cochrane review database. The keywords used were as follows: \"Taurolidine\"; \"taurolidine-citrate\"; \"taurolock\" \"catheter-related Infection\"; \"catheter-related sepsis\" and\"hemodialysis\".

*Population:* Hemodialysis Patients

*Intervention:* Taurolidine-Citrate

*Comparators:* Heparin and Heparin-Gentamicin

*Outcomes:* Studies were included in the clinical review if they reported primary data on one or more of the following outcomes: "CRB episode", which is defined as the percentage of patients with bacterial infection due to the catheter; "CRB-free survival", which is defined as the cumulative survival rate without bacterial infection related to catheters in 90 days; and "catheter thrombosis rate", which is defined as the incidence rate of catheter thrombosis.

*Inclusion Criteria:* Studies were considered eligible for inclusion if they met the following criteria:

*Study Design:* The published articles had to be written in English, utilized randomized controlled trials (RCTs) method, meta-analysis and economic evaluation, and had to directly evaluate the clinical efficacy of taurolidine-citrate compared to alternatives. In other words, the studies focused on the following question: \"Does taurolidine-citrate reduce the catheter-related infections and thrombosis, compared to heparin and heparin-gentamicin, in the hemodialysis patients?\"

*Exclusion Criteria:* All in vivo and animal studies, uncontrolled, observational, and biochemical effects studies and A Jadad score of less than 3 were excluded.

*Data extraction:* Two authors separately examined the results of our systematic search through reviewing the titles and abstracts and eliminated duplicates and unrelated reports and those meeting the exclusion criteria. Then the reports selected by the authors were rechecked to make a decision about including them in the study. In the next step, the full texts of the remaining articles were assessed to evaluate the inclusion and exclusion criteria in each of them and to select the final studies.

*Assessment of the Trial Quality:* The methodological quality of all included studies was evaluated by the Jadad score, assigning a score of 0 to 5 to each study based on randomization, blinding and dropouts (withdrawal). The score of two was given to the study if appropriate methods of randomization was described, the score of one was assigned to those studies , which were merely described as 'randomized', and the score of zero was given when no details were provided to evaluate randomization. Two points can be given for blinding in the study: A score of two were allocated if patients and investigators were made blind by appropriate methods; the score of one was given if the study was described merely as double blind; and the score of zero was allotted if details about blinding were not provided. The third item to be scored was the reporting of withdrawals. The study received a score of one if all patients were accounted for in the analysis, and reasons for withdrawals were provided. A score of zero was given when information regarding withdrawals was incomplete. In this method, scores ≥ 3 were considered as acceptable in terms of quality. A Jadad score of less than 3 was considered as an exclusion criterion ([@R13]).

2) Evidence Synthesis {#s2-2}
---------------------

*Statistical Analysis:* Data were extracted and formed in 2 × 2 tables by study characteristics and were analyzed using Stata software version 2.7.9. Relative differences (RD) and 95% confidence intervals (95% CI) were calculated using Mantel-Haenszel, Greenland-Robins (for fixed effects) or Der Simonian-Laird (for random effects) methods. The Cochran Q test was used to test heterogeneity, and p\< 0.05 was considered statistically significant. In case of heterogeneity or insufficiency of the included studies, the random effects model was used. Funnel plot was used as a publication bias indicator. Clinical importance was evaluated by the Edwards-Nunnally method.

3) Cost-effectiveness Analysis {#s2-3}
------------------------------

The model was structured as an initial decision tree, in which hemodialysis patients entered at the initiation of the treatment, and received taurolidine-citrate or heparin or heparin-gentamicin. Followed by the subtree for each strategy option, the condition was followed through treatment, including any number of possible outcomes. At each terminal node, values for cost and effectiveness were associated with that outcome. Probabilities of the subtree in the decision tree model were obtained from the studies. A time frame of 3 months was considered‏.

*Effectiveness Analysis:* The outcome of interest in this cost-effectiveness study was \"reduction of catheter-related infection\". The results of meta-analysis were used to extract the probability of experiencing at least one infection during three months. The probabilities of CRB and re-catheterization after using antibiotics was also extracted from Filiopoulos and TvanaiiSani´s studies ([@R10],[@R16]).

*Cost:* To estimate the costs associated with taurolidine and alternatives, we consulted a group of nephrology specialists. In this study, direct medical costs, including the costs of catheter, taurolidine, heparin, and gentamicin, antibiotics, hospitalization, etc. were included in the analysis. The payer's (patients and insurer) perspectives were used for cost analysis. To exchange the prices from Iranian Rials (IRR) to US Dollars (USD), we used the exchange rate announced by the Central Bank in 2014, which was 26,670 Rials per Dollar. A hypothetical cohort of 1,000 people was used to run the model and probabilities obtained from the studies.

*Incremental Cost-Effectiveness Ratio (ICER):* ICER was calculated based on the results of the effectiveness and cost of each of the three mentioned drugs (taurolidine-citrate, heparin, and gentamicin-heparin).

*Sensitivity Analysis:* To test the robustness of our results, a sensitivity analysis was carried out by considering the uncertainty of the key parameters. The one-way sensitivity analysis was performed, and the value of each variable was increased by 20%; a tornado diagram was used to present the results.

Results {#s3}
=======

After the initial search, 1,157 articles were identified including 231 articles from PubMed, 647 from Scopus, 235 from ISI, and 44 from Cochrane. After carrying out the systematic process on the searched studies with regards to the inclusion and exclusion criteria, only three articles were recognized as suitable for analysis ([@R8],[@R10],[@R17]). The full process of the study selection is demonstrated in [Fig. 1](#F1){ref-type="fig"}. All three studies were randomized clinical trials, in which the efficacies of these drugs were reported. A summary of the selected studies about alternatives, dose prescription and the number of patients is listed in [Table 1](#T1){ref-type="table"}. Jadad Score of all studies were 3 or higher, so we included all of them in the final analysis.
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###### Characteristics of the Selected Studies in the Systematic Review and Effectiveness of Heparin and Taurolidine-Citrate Based on Three Outcomes

  ------------------ ---------------------------------------------------- --------------------------- ------------------------- ------------------------------------------------------------------------------ ------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------
  Study              Arms of study                                        Number of patients          Average of Patients Age   Dose & Route of Treatment                                                      Effectiveness                                                                                                                                   

  CRB eEpisode\      CRB-Free Catheter Survival\                          Catheter Thrombosis rate\                                                                                                                                                                                                                                                            
  (Incidence n(%))   (cumulative CRB-free catheter survival at 90 days)   N (%)                                                                                                                                                                                                                                                                                

  Filiopoulos V,\    (A): Gentamicin/heparin-\                            60-59-58                    (A): 72 (50-80)\          (A): 40 mg/ml gentamicin and 5,000 U/ml unfractionated heparin; ratio 1:3\     (A): 6(10%);\                         (A): 82%\                                                                                                 (A): 11 (14.86%)\
  et al., 2011       (B): Taurolidine/citrate\                                                        (B): 75 (36-95)\          (B):1.35% taurolidine and 4% sodium citrate; TauroLock TM , TauroPharm GmbH\   (B): 8(13.5%)\                        (B): 78%\                                                                                                 (B): 9 (11.84%)\
                     (C): Heparin                                                                     (C): 70 (42-84)           (c): heparin 5,000 U/ml                                                        (C): 20(34.48)\                       (C): 26%\                                                                                                 (C): 6 (8.95%)\
                                                                                                                                                                                                               \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\   \*\*\*\*\*\*\*\*\*\*\*\*\                                                                                 \*\*\*\*\*\*\*\*\*\*\*\*\
                                                                                                                                                                                                               (A) vs (C): χ²= 6.62,\                (A) vs (C): log-rank 3.03,\                                                                               A) vs (B):χ²= 0.23,\
                                                                                                                                                                                                               p= 0.01\                              p= 0.002\                                                                                                 p= 0.63: N sig\
                                                                                                                                                                                                               (B) vs (C): χ²= 4.34,\                (B) vs (c):log-rank 2.63,\                                                                                (A) vs (C): χ²= 0.91,\
                                                                                                                                                                                                               p= 0.03.\                             p= 0.008\                                                                                                 p= 0.33: N sig\
                                                                                                                                                                                                               (A) vs (B): N sig                     (A) vs (B): N sig                                                                                         (B) vs (c):χ²= 0.26,\
                                                                                                                                                                                                                                                                                                                                                               p= 0.61: N sig

  Solomon LR,\       (A): Taurolidine/citrate\                            53-54                       )A): 59.8±14.7\           (A):1.35% taurolidine and 4% citrate\                                          (A):9 (17%)\                          Not reported                                                                                              (A): 28 (53%)\
  et al., 2010       (B): Heparin                                                                     (B): 56.7±17.4            (B): Heparin (5,000 U/mL)                                                      (B): 16 (30%)\                                                                                                                                  (B): 14 (26%)\
                                                                                                                                                                                                               \*\*\*\*\*\*\*\*\*\*\*\*\*\                                                                                                                     \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\
                                                                                                                                                                                                               p=0.1: (A) vs (B): N sig                                                                                                                        p= 0.006; significant

  Betjes MGH,\       (A): Taurolidine/citrate\                            28-28                       (A): 58.3±16.3\           (A):1.35% taurolidine and 4% citrate;\                                         (A):0\                                the sepsis-free survival was significantly lower in patients \[B\] compared with \[A\] group (p= 0.047)   Not reported
  et al., 2004       (B): Heparin                                                                     (B): 50.3±20.4            (B): Heparin (5,000 U/mL)                                                      (B): 4 (14%)\                                                                                                                                   
                                                                                                                                                                                                               \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\                                                                                                               
                                                                                                                                                                                                               p= not reported                                                                                                                                 
  ------------------ ---------------------------------------------------- --------------------------- ------------------------- ------------------------------------------------------------------------------ ------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------

The selected studies were assessed for three outcomes including: "CRB episode", "CRB-free catheter survival" and "catheter thrombosis rate". Based on these outcomes, the results of the three studies were extracted ([Table 1](#T1){ref-type="table"}).

CRB Episode: The outcome of CRB episode was investigated in all studies. According to [Table 1](#T1){ref-type="table"}, CRB episode was 12.14% (17/140) in taurolidine-citrate group and 28.57% (40/140) in the heparin group. The result of meta-analysis revealed that, with 95% confidence interval, the risk difference for CRB episode was -0.16 (-0.25 to -0.07), ([Fig. 2](#F2){ref-type="fig"}). The Cochrane Q test for heterogeneity indicated that the studies were not heterogeneous (p= 0.71) and could be combined. However, the random effects for individual and summary for RD was applied due to the small number of the studies included in the review. Publication bias for "CRB" in patients, among taurolidine versus alternative therapies, could not be evaluated due to the very few strata.
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Catheter Thrombosis Rate: The outcomes of catheter thrombosis were determined in two studies ([@R8],[@R10]). Catheter thrombosis rate was 14.28% (20/140) in taurolidine-citrate group and 26.42% (37/140) in the heparin group. The meta-analysis showed a risk difference of l0.13 (-0.06-0.32) for CRB episode, with 95% confidence interval ([Fig. 3](#F3){ref-type="fig"}).
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The Cochrane Q test for heterogeneity indicated that the studies were not heterogeneous (p= 0.08) and could be combined. However, the random effects for individual and summary for RD was applied due to the very few included studies. Moreover, publication bias for the included studies could not be evaluated between taurolidine and alternative therapies in patients due to the very few strata.

Cost-Effectiveness Analysis: In this study, direct medical costs including the costs of catheter, taurolidine-citrate, heparin and gentamicin, antibiotics, hospitalization, etc. were included in the analysis. A decision tree model was used ([Fig. 4](#F4){ref-type="fig"}), and the probabilities of the decision tree model were obtained from the available evidences ([Table 2](#T2){ref-type="table"}). Moreover, the overall cost per 1,000 populations was calculated using the decision tree model. Also, prevention of catheter-related infection was considered as the outcome, which was obtained from previous studies ([@R10]).
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###### Probability of CRB Free, CRB and Re Catheterization

  --------------------- -------------------- ------ ----------
  Probabilities         Re catheterization   CRB    CRB free
  Taurolidine-citrate   0.33                 0.22   0.78
  Heparin               0.33                 0.74   0.26
  Heparin-gentamicine   0.33                 0.18   0.82
  --------------------- -------------------- ------ ----------

The total direct cost of taurolidine-citrate was \$236,697 and the cost of heparin and heparin/gentamicin was \$162,088.1 and \$37,750.68, respectively. In addition, the effectiveness of taurolidine-citrate, heparin and heparin/gentamicin was 780, 260 and 820 CRB free patients, respectively ([Table 3](#T3){ref-type="table"}).

###### The Cost and Effectiveness of Taurolidine-Citrate, Heparin, and Gentamicin/Heparin

  --------------------- ------------ --------------- ------------------ ----------------------------- ------------------------------
  Drugs                 Total cost   effectiveness   ICER\              ICER\                         ICER\
                                                     (versus Heparin)   (versus Heparin/gentamicin)   (versus taurolidine citrate)

  Taurolidine-citrate   236697.4     780             143.48             -4973.67                      NA

  Heparin               162088.1     260             NA                 Not calculated                143.48

  Heparin-gentamicin    37750.68     820             Not calculated     NA                            -4973.67\
  --------------------- ------------ --------------- ------------------ ----------------------------- ------------------------------

The ICER was calculated to compare taurolidine-citrate locks solution with both heparin and heparin-gentamicin combination. The results of this analysis indicated that the ICER for taurolidine-citrate and heparin was estimated to be \$143.8, so in order to make decisions it should be compared with a threshold. The recommendation of the World Health Organization was considered as the threshold, in which the ICER between one to three times of the GDP per capita is considered as cost-effective, but the ICER of more than three times is not cost-effective ([@R18]). Based on the report of the central bank of Iran, the GDP was 4,670 Dollars in 2014, three times of which is 14,010 Dollars. Considering that the ICER is \$143.8 and it is lower than this threshold, taurolidine-citrate is more cost-effective and a superior strategy compared to heparin. Nevertheless, compared to heparin-gentamicin combination, taurolidine-citrate is an inferior strategy due to its higher cost and lower infection prevention. The ICER for taurolidine-citrate and heparin-gentamicin was estimated -4,973.67 USD.

Sensitivity Analysis: To test the robustness of our results, we conducted a sensitivity analysis by considering the uncertainty of the key parameters. The one-way sensitivity analysis was performed and the value of each variable was increased by 20%; the results were presented using a tornado diagram. Tornado diagram for taurolidine-citrate, indicated that cost-effectiveness ratio was most sensitive to the effectiveness of taurolidine-citrate, and least sensitive to the cost of taurolidine-citrate compared to heparin, ([Fig. 5](#F5){ref-type="fig"}). Moreover, tornado diagram for taurolidine-citrate comparing heparin-gentamicin indicated that cost-effectiveness ratio was most sensitive to the effectiveness of taurolidine-citrate. In addition, the ICER compared to the 20% increase in the cost of heparin-gentamicin, is very robust and its effect is not shown in the diagram ([Fig. 6](#F6){ref-type="fig"}).
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Discussion {#s4}
==========

According to the results of the meta-analysis and based on the outcome of the \"rate of catheter-related thrombosis", there was no statistically significant difference between the levels of effectiveness of taurolidine-citrate and heparin. This study also revealed that taurolidine-citrate was a superior option compared to heparin and an inferior strategy (higher cost and lower efficacy) compared to heparin-gentamicin combination.

Filiopoulos et al. ([@R10]) in their study, found that the rate of CRBSI in taurolidine-citrate was significantly lower than heparin (p=0.03), but the rate of CRBSI was higher in taurolidine-citrate group in terms of prevention of thrombosis; however, it was not statistically significant (p= 0.61). Overall, when heparin is used in combination with antibiotics, CRBSI rate will become lower compared to taurolidine-citrate, but the difference is not statistically significant, meaning that the heparin-antibiotic can be more effective than taurolidine-citrate. On the other hand, taurolidine-citrate does not cause bacterial resistance ([@R19]) and this can be an advantage for taurolidine-citrate. In an observational study ([@R20]), Solomon et al. showed that the amount of bacteria after using taurolidine-citrate-heparin, taurolidine-citrate, and heparin was 1.33,1.22, and 3.25 per 1,000 catheter days, respectively. Moreover, adding 500 ml heparin to taurolidine-citrate reduced thrombosis, without an increase in bacteremia, which increased performance compared to heparin.

In another study, Taylor et al. ([@R21]) examined the use of catheter lock taurolidine-citrate in hemodialysis patients in a hospital. They found that the use of taurolidine-citrate, compared to heparin, reduced infections by 85%, as well as the costs and had a positive impact on mortality. Other studies, which were conducted on cancer patients and home parental nutrition, showed that taurolidine-citrate significantly reduced the rate of catheter-related infections ([@R22]-[@R24]) and resulted in significant savings in costs ([@R25]).

Conclusion {#s5}
==========

The results of this study were consistent with those of previous studies and revealed that taurolidine-citrate has a positive impact on the prevention of catheter-related infections. The result of meta-analysis revealed that the rate of catheter-related infections in hemodialysis patients that have used taurolidine-citrate was 16% less compared to hemodialysis patients who received heparin; and the difference was significant in the incidence of catheter-related thrombosis infections. On the other hand, the rate of catheter-related thrombosis in hemodialysis patients that have used taurolidine-citrate was 13% more compared to hemodialysis patients who received heparin. However, the difference was not significant in the incidence of thrombosis. Considering that taurolidine-citrate has advantages over heparin, more attention should be paid to its benefits in the decision-making process. As mentioned in the results, taurolidine-citrate is an antifungal agent that does not cause bacterial resistance, so if antibiotics are used in combination with heparin, taurolidine-citrate can be more advantageous compared to heparin/antibiotic.

In this search, we could not find any published meta-analysis and cost- effectiveness analysis in electronic databases. The results of the current meta-analysis may be used in different settings to evaluate the efficacy based on available clinical evidences. However, the clinical evidences on taurolidine-citrate, heparin and gentamicin/heparin are not enough for making certain decisions. In addition, the results of cost- effectiveness analysis indicated that in spite of the higher cost of taurolidine-citrate compared to heparin, the total cost is much higher due to the utilization of heparin, and because of the higher rate of catheter-related infection, this new introduced technology can be applied by professionals at the health sector.

In this study, we were faced with some limitations. First, the number of clinical trials evaluating the efficacy and the safety of taurolidine citrate was limited. In addition, the comparator arm in the available RCTs was heparin, and we found only one observational study comparing it to gentamicin. As the clinical efficacy of taurolidine is not compared with other antimicrobial alternatives in available RCTs, the absence of this comparison can be a weakness. The results of the current meta-analysis and cost effectiveness analysis were based on the available clinical evidences on taurolidine- citrate. Therefore, more RCTs comparing the efficacy and safety of taurolidine- citrate with both gentamicin and other antibiotics and anticoagulants, should be piloted and published for more robust results, particularly when these results are used for public health policy making and priority setting.

###### Search Strategies

  ---------------------- ----------- -------------------------------------------------------------- -----------------------
  Data Base              Years       Search Strategies                                              References Identified

  PubMed                 1996-2013   1)"Taurolock" OR "Taurolidin citrate"\                         231
                                     2)"Catheter-related Infection" OR "Catheter-related sepsis"\   
                                     3)Hemodilysis\                                                 
                                     4)Heparin lock\                                                
                                     5)"1" AND "2"\                                                 
                                     6)"1" AND "3"\                                                 
                                     7)"1" AND "4"                                                  

  Scopus                                                                                            235

  Web of knowledge ISI                                                                              647

  Cochrane                                                                                          44

  Total                                                                                             1157
  ---------------------- ----------- -------------------------------------------------------------- -----------------------

###### What are these studies and their design, aims and results?

  ---------------------- --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                  Study Design    Aim                                                                                                                                                                                                                                 Result

  Filiopoulos V (2011)   RCT             Compare gentamicin/ heparin and taurolidine/ Citrate and control group (heparin)                                                                                                                                                    Both antimicrobial lock solutions were superior to heparin in CRB prevention with similar thrombosis rates.

  Solomon R (2010)       RCT             Comparing taurolidine-citrate catheter locks with heparin catheter locks started at the time of catheter insertion in hemodialysis patients using tunneled cuffed intravascular catheters                                           Taurolidine-citrate use did not decrease all-cause bacteremia and was associated with a greater need for thrombolytic treatment. There was a decrease in infections caused by Gram-negative organisms and a trend to a lower frequency of bacteremia

  Betjes M (2004)        RCT             Tested the efficacy of citrate--\                                                                                                                                                                                                   Catheter filling with a solution containing the antimicrobial taurolidine may significantly reduce the incidence of catheter related sepsis. Taurolidine appears to be effective and safe and does not carry the risk for side effects that have been reported for other antimicrobial lock solutions containing gentamicin or high concentrations of citrate.
                                         taurolidine lock solution compared with heparin in the prevention of Catheter-related sepsis.                                                                                                                                       

  Taylor C (2008)        Observational   Investigating the use of a taurolidine/ citrate catheter-locking agent for patients receiving hospital-based haemodialysis, auditing the number and cost of infections before and after its introduction.                           The use of a taurolidine/citrate haemodialysis catheter-locking agent in our haemodialysis population has significantly reduced the line sepsis rate, with a positive impact on morbidity, mortality and cost.

  Du¨michen M (2012)     RCT             To compare the impact on microbial catheter colonization and infectious complications of heparin and taurolidine citrate as central venous catheter (CVC) lock solutions in paediatric patients with haematological malignancies.   Use of taurolidine citrate lock solution was associated with significantly fewer primaries BSI.

  Simon A (2008)         Cohort          investigated the impact of a taurolidine/citrate containing central venous access device lock solution on catheter-associated infections in a pediatric oncology                                                                    The use of Taurolidin/Citrate (TauroLock™) significantly reduced the number and incidence density of primary catheter-associated bloodstream infection in pediatric cancer patients.

  Rafferty G (2010)      Cohort          The primary aim was to determine the incidence of CRBSI prior and subsequent to Taurolock® use. The secondary aim was to establish cost benefit from Taurolock® prescription.                                                       Taurolock® significantly decreases CRBSI rate in HPN patients and generates considerable cost savings in this cohort of patients.

  Taniguchi A (2009)     Observational   investigated the Effectiveness of TaurolockTM in preventing recurrent catheter-related bloodstream infections in patients on home parenteral nutrition                                                                              TaurolockTM proved to be effective in reducing CRBSI significantly in patients with recurrent infections, with acceptable adverse event profile.
  ---------------------- --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
